Dispensation of hormonal contraceptive agents in a community pharmacy of Valladolid (Spain)
Keywords:
Dispensing, Community pharmacy, Hormonal contraceptive agents, Adverse effects, Medication adherenceAbstract
Aims: To know the risk factors for users of hormonal contraceptives (HC), HC previously used, reason for the change of HC referred by the user, dispensing HC, adverse effects presented with the last used HC and if she forgot to take/use the HC correctly.
Material and methods: Observational, descriptive, cross-sectional study by means of an administered questionnaire to users who attended a community pharmacy of Valladolid.
Results: 120 users responded to the questionnaire. The 43.3 per cent had risk factors added to suffer a cardiovascular event (hypercholesterolemia, smoking, diabetes, etc.) and the 3.3 per cent had at least a relative contraindication for its use. The HC used previously in most occasions was “cyproterone 2 mg + ethinylestradiol 35 μg tablets”. The users changed HC mainly by the presence of adverse effects. The most dispensing HC were those who had as progestin drospirenone. The most common side effects of the HC in use were headaches, weight gain, irregular spots and mood changes. The 36.4 per cent of the patients admitted to having forgotten to take/use the HC correctly and the (29.7 per cent) did not know what they would have to do in case of forgetfulness.
Conclusions: Almost half of the users had risk factors added to suffer a cardiovascular event. The user said that she had changed from HC mainly by adverse effects. The most dispensing HC contained as progestin drospirenone. The 36.4 per cent of the users forgot to take/use the HC correctly. It is necessary to promote multidisciplinary educational campaigns to improve the use of these medications.
Downloads
References
Ruiz-Muñoz D, Pérez G. Women's socioeconomic factors associated to the choice of contraceptive method in Spain. Gaceta Sanitaria. 2013; 27(1): 64-67.
Equipo DAPHNE. VII Encuesta de Bayer HealthCare de Anticoncepción en España 2011. Disponible en: http://www.equipodaphne.es/otrasencuestas.php?y=2011.
SEC: Sociedad Española de Contracepción [Internet]. Grupo de trabajo sobre anticoncepción oral. Manual de anticoncepcion hormonal oral. Sociedad Espanola de Contracepcion. [acceso 7 de febrero de 2013]. Disponible en: http://www.sec.es/area_cientifica/manuales_sec/aho/aho.php
Lete I, Dueñas JL, Serrano I et al. Actualización en Medicina de Familia. Efectos beneficiosos no anticonceptivos de la píldora anticonceptiva. Semergen. 2009; 35: 505-510.
David PS, Boatwright EA, Tozer BS, Verma DP, Blair JE. Hormonal contraception update. Mayo Clin Proc. 2006; 81(7): 949-54.
Čepulienė R, Sveikatienė R, Gutauskas K, Vanagienė V. Factors influencing women's preference to select a combined hormonal contraceptive method: a cross-sectional survey in Lithuania. Medicina (Kaunas). 2012; 48(8): 424-30.
Alén de la Torre MT, Martínez Leirós M, Pereiro Álvarez MD, Ferreira Meira M, García Merino V. Valoración de las nuevas vías de administración de anticonceptivos hormonales por sus usuarias. Farmacéuticos comunitarios. 2010; 2(1): 21-22.
Martinez F, Avecilla A. Combined hormonal contraception and venous thromboembolism. Eur J Contracept Reprod Health Care. 2007; 12(2): 97-106.
López de Castro F, Lombardía Prieto J. Novedades en anticoncepción hormonal. Inf Ter Sist Nac Salud. 2005; 29 (3):57-68.
Lee J, Jezewski MA. Attitudes toward oral contraceptives use among women of reproductive age: a systematic review. ANS Adv Nurs Sci. 2007; 30(1): 85-103.
De la Cuesta Benjumea R, Franco Tejeda C, Iglesias Goy E. Actualización en anticoncepción hormonal. Inf Ter Sist Nac Salud. 2011; 35(3): 75-87.
Ley Orgánica 2/2010, de 3 de marzo, de salud sexual y reproductiva y de la interrupción voluntaria del embarazo. L. Nº 55/2010 (4 marzo 2010).
Cardo Prats E; Baixauli Fernandez VJ. Dispensacion de anticonceptivos orales según el consenso de atención farmacéutica. Offarm. 2004; 23 (11): 76-85.
Foro de Atención Farmacéutica, panel de expertos. Documento de Consenso, Enero de 2008. Madrid: Consejo General de Colegios Oficiales de Farmacéuticos; 2008.
Foro de Atención Farmacéutica. Farmacia Comunitaria. Guía práctica para los servicios de atención farmacéutica en la farmacia comunitaria. Madrid: Ed. Consejo General de Colegios Oficiales de Farmacéuticos; 2010. 56 p.
Consejo General de Colegios Oficiales de Farmacéuticos. BOT plus. Base de Datos del Conocimiento Sanitario [CD]. Madrid: Consejo General de Colegios Oficiales de Farmacéuticos; 2012.
Vela Blanco RM. Tabaquismo y riesgo cardiovascular en usuarias de anticonceptivos hormonales. [master atención farmacéutica]. Granada: Universidad de Granada; 2011.
Kroon LA. Am J Health Syst Pharm. Drug interactions with smoking. 2007; 64(18): 1917-1921.
Petruta A, García-Jiménez E, Martínez F, Moreno A. Grado de conocimiento sobre el uso de anticonceptivos hormonales en una farmacia comunitaria en Zaragoza. Ars Pharm. 2009; 50(1): 1-7.
Petruta Dimitriu A. Grado de conocimiento sobre el uso de los anticonceptivos hormonales en las farmacias de la provincia de Zaragoza. [master atención farmacéutica]. Granada: Universidad de Granada; 2009.
Ferrer I, Murillo MD, Machuca M. Determinación del grado de conocimiento y correcta utilización sobre anticonceptivos orales en farmacia comunitaria. Seguim Farmacoter. 2003; 1(3): 136-138.
Ley 42/2010, de 30 de diciembre, por la que se modifica la Ley 28/2005, de 26 de diciembre, de medidas sanitarias frente al tabaquismo y reguladora de la venta, el suministro, el consumo y la publicidad de los productos del tabaco. L. Nº 318/2010 (31 diciembre 2010).
Johnson S, Pion C, Jennings V. Current methods and attitudes of women towards contraception in Europe and America. Reproductive Health. 2013 (en prensa).
AEMPS [Internet]. La AEMPS informa. Informe mensual. Mayo 2011. Medicamentos de uso humano. [acceso 8 de febrero de 2013]. Disponible en: http://www.aemps.gob.es/informa/informeMensual/2011/mayo/informe-medicamentos.htm
Sidney S, Cheetham TC, Connell FA et al. Recent combined hormonal contraceptives (CHCs) and the risk of thromboembolism and other cardiovascular events in new users. Contraception. 2013; 87(1): 93-100.
Gronich N, Lavi I, Rennert G. Higher risk of venous thrombosis associated with drospirenone-containing oral contraceptives: a population-base cohort study. CMAJ. 2011; 183 (18): 1319-1325.
Molinero Crespo AM, de Diego Martínez C, Esteso P, et al. Características de la utilización de anticonceptivos hormonales orales a través del servicio de dispensación en la farmacia comunitaria. Farmacéuticos Comunitarios. 2010; 2 (2): 56-61.
Moreau C, Cleland K, Trussell J. Contraceptive discontinuation attributed to method dissatisfaction in the United States. Contraception. 2007; 76(4): 267-272.
Carbajal-Ugarte JA, Cárdenas-Blanco A, Pastrana-Huanaco E, López-Berrios D. Eficacia y efectos adversos de anticonceptivos hormonales. Estudio comparativo. Rev Med Inst Mex Seguro Soc. 2008; 46 (1): 83-87.
Grossman Barr N. Managing adverse effects of hormonal contraceptives. Am Fam Physician. 2010; 82(12): 1499-1506.
Pittman ME, Secura GM, Allsworth JE, Homco JB, Madden T, Peipert JF. Understanding prescription adherence: Pharmacy claims data from the Contraceptive CHOICE Project. Contraception. 2011; 83(4): 340–345.
Halpern V, López LM, Grimes DA, Gallo MF. Strategies to improve adherence and acceptability of hormonal methods of contraception (Review). The Cochrane Library, Editorial John Wiley Sons, Ltd. 2011; 35p. (http://thecochranelibrary.com).
INE [Internet]. Estadísticas del Padrón Continuo a 1 de enero de 2012. Datos por municipios: Valladolid. Población por sexo, municipio y edad (año a año). [acceso 8 de febrero de 2012]. Disponible en: http://www.ine.es/jaxi/tabla.do
Downloads
Published
How to Cite
Issue
Section
License
The articles, which are published in this journal, are subject to the following terms in relation to the rights of patrimonial or exploitation:
- The authors will keep their copyright and guarantee to the journal the right of first publication of their work, which will be distributed with a Creative Commons BY-NC-SA 4.0 license that allows third parties to reuse the work whenever its author, quote the original source and do not make commercial use of it.
b. The authors may adopt other non-exclusive licensing agreements for the distribution of the published version of the work (e.g., deposit it in an institutional telematic file or publish it in a monographic volume) provided that the original source of its publication is indicated.
c. Authors are allowed and advised to disseminate their work through the Internet (e.g. in institutional repositories or on their website) before and during the submission process, which can produce interesting exchanges and increase citations of the published work. (See The effect of open access).
